Rubella seroprevalence among women aged 15-39 years in Morocco

Eastern Mediterranean Health Journal

Volumn 15, Issue 3, 2009, Pages 526-531

  Caidi, H ^a,d   Bloom, S ^b   Azilmaat, M ^c   Benjouad, A ^d   Reef, S ^b   El Aouad, R ^a  

^a INSTITUT NATIONAL D HYGIÈNE   (Morocco)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

^c Ministry of Health Morocco   (Morocco)

^d MOHAMMED V UNIVERSITY   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGE DETERMINATION; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MOROCCO; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; RUBELLA; RURAL AREA; SEROLOGY; SEROPREVALENCE; URBAN AREA; VACCINATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; LIKELIHOOD FUNCTIONS; MOROCCO; NEEDS ASSESSMENT; REPRODUCTIVE MEDICINE; RISK FACTORS; RUBELLA; RUBELLA VIRUS; RURAL POPULATION; SEROEPIDEMIOLOGIC STUDIES; SEX DISTRIBUTION; URBAN POPULATION; VACCINATION; WOMEN'S HEALTH;

EID: 69949122119     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2009.15.3.526     Document Type: Article

References (23)

1. Roberston SE et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries. Part 2: Vaccination against rubella. Bulletin of the World Health Organization, 1997, 75:69-80.
2. De Nobrega M, Maurice WLL, Juliano Y. Study of the hearing loss in children and adolescents, comparing the periods of 1990-1994 and 1994-2000. International journal of pediatric otorhinolaryngology, 2005, 69:829-38.
3. Jazbec A, Delimar M, Vrzic VS. Simulation model of rubella, the effects of vaccination strategies. Applied mathematics and computation, 2004, 153:75-96.
4. Centers for Diseases Control. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and mortality weekly report, 1998, 47(RR-8):1-57.
5. Control of rubella and congenital rubella syndrome (CRS) in developing countries. Geneva, World Health Organization, 2001 (WHO/ V&B/00.03).
6. Kanbur NO et al. Age specific rubella seroprevalence of an unvaccinated population of adolescents in Ankara, Turkey. Japanese journal of infectious disease, 2003, 56:23-5.
7. Santé en chiffre 2005. Edition 2006. Rabat, Ministry of Health, 2005 (http://www.sante.gov.ma/Departements/dprf/SEIS/ SanteEnChiffres.htm, accessed 27 January 2008).
8. Nejmi S, Nazih A, Omri B. Enquête immunologue sur la rubéole chez la femme Marocaine de la région de Rabat [Immunological survey of rubella in women of the Moroccan region of Rabat]. Maroc médicale, 1972, 52:420-5.
9. Nejmi S, L'Kassmi H. Profil immunitaire de la femme Marocaine vis-à-vis de la rubéole et de la toxoplasmose. Enquête immunologique sur la rubéole chez la femme Marocaine de la région de Rabat et de Meknès [Immune profile of Moroccan women vis-à-vis rubella and toxoplasmosis. Immunological survey of rubella in women of the Moroccan region of Rabat and Meknes]. Paper presented at the Fifth National Congress of Neonatology, Meknès, Morocco, 2003.
10. Bloom S et al. Congenital rubella syndrome burden in Morocco: a rapid retrospective assessment. Lancet, 2005, 365:135-41.
11. Azelmat M. 1997 National survey on mother and child health (PAPCHILD). Rabat, Ministry of Health, and Cairo, Arab League, 1999.
12. Doroudchi M et al. Seroepidemiological survey of rubella immunity among three populations in Shiraz, Islamic Republic of Iran. Eastern Mediterranean health journal, 2001, 7(1/2):128-38.
13. Dromigny JA, Nabeth P, Perrier Gros Claude JD. Evaluation of the seroprevalence of rubella in the region of Dakar (Senegal). Tropical medicine and international health, 2003, 8(8):740-3.
14. Dykewicz CA et al. Rubella seropositivity in the United States, 1988-1994. Clinical infectious diseases, 2001, 33:1279-86.
15. Cutts FT, Vynnycky E. Modelling the incidence of congenital rubella syndrome in developing countries. International journal of epidemiology, 1996, 28:1176-84.
16. Cutts FT et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries. Part 1: Burden of disease from CRS. Bulletin of the World Health Organization, 1997, 75:55-68.
17. Bouazzaoui L. Consanguinité et santé publique au Maroc [Consanguineous marriages and public health in Morocco]. Bulletin de l'Académie nationale de médecine, 1994, 178:1013-27.
18. Durkin MS et al. Prenatal and postnatal risk factors for mental retardation among children in Bangladesh. American journal of epidemiology, 2000, 152:1024-33.
19. Hinman AR et al. Economic analyses of rubella and rubella vaccine: a global review. Bulletin of the World Health Organization, 2002, 80:264-70.
20. Roberston SE et al. Rubella and congenital rubella syndrome: global update. Revista Panamericana de salud publica, 2003, 14(5):306-15.
21. Davidkin I et al. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine, 2000, 18(27):3106-12.
22. Wysokiñska T et al. The prevalence of anti-rubella antibodies in women of childbearing age in Poland. Vaccine, 2004, 22:1899-902.
23. Vynnycky E, Gay NJ, Cutts FT. The predicted impact of private sector MMR vaccination on the burden of congenital rubella syndrome. Vaccine, 2003, 21:2708-19.